Fresenius Targets Nostrum’s Generic PhosLo GelCaps

Law360, New York (January 17, 2012, 2:44 PM EST) -- Fresenius Medical Care Holdings Inc. on Friday lodged a patent infringement suit in Massachusetts federal court in an effort to block Nostrum Laboratories Inc. from marketing a generic version of kidney failure treatment PhosLo GelCaps.

Fresenius lodged the suit after Nostrum filed an abbreviated new drug application with the U.S. Food and Drug Administration to sell a calcium acetate drug — the generic form of PhosLo GelCaps — which is used in end-stage renal failure to boost calcium levels and combat high levels of phosphate in...
To view the full article, register now.